Cadrenal Therapeutics (NasdaqCM:CVKD) 2025 Conference September 30, 2025 03:30 PM ET Company ParticipantsTerry Ferguson - Chief Medical OfficerModeratorAll right, hello everyone. Thank you so much for joining us throughout the day here at the Lytham Partners Fall 2025 Investor Conference. Again, my name is Robert Blum, Managing Partner here at Lytham Partners. Coming up next, we have a presentation from Cadrenal Therapeutics, company trades under the ticker symbol CVKD on the NASDAQ. Presenting from the com ...

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tu ...

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tu ...

收购概述 - Cadrenal Therapeutics公司宣布收购eXIthera Pharmaceuticals公司的资产，包括其专有的静脉注射和口服因子XIa抑制剂研究产品组合 [1] - 此次收购显著增强了公司的产品管线，新增的候选药物针对当前价值380亿美元全球抗凝市场中规模庞大且服务不足的细分领域 [1] - 收购使公司成为全球唯一一家同时开发新型维生素K拮抗剂和因子XIa抑制剂的公司 [3] 收购资产详情 - 核心资产frunexian是一款同类首创、已准备进入二期临床试验的静脉注射因子XIa抑制剂，适用于急性护理场景 [2] - 另一项资产EP-7327是一种口服因子XIa抑制剂，用于预防和治疗主要血栓性疾病 [2] - 收购还包括大量额外的创新型因子XIa小分子药物组合 [9] 战略定位与市场机会 - 收购强化了公司成为抗凝治疗领域领导者的长期愿景 [4] - 公司战略定位旨在为整个心血管血栓风险谱系的患者提供差异化疗法 [4] - 因子XIa抑制是当前血栓形成研究中最活跃和令人兴奋的领域之一 [3] 交易条款 - 根据收购协议条款，eXIthera将获得来自公司的里程碑付款，总额最高达1500万美元，具体取决于未来特定临床和监管里程碑的实现 [6] - eXIthera还有权在资产未来商业化后获得全球销售额的分成 [6] - 根据一项预先存在的许可协议，四川海思科药业股份有限公司保留frunexian在中国的权利，公司有权获得frunexian在中国未来销售的版权费 [5] 公司现有核心产品 - 公司的主要研究产品是tecarfarin，一种新型口服维生素K拮抗剂抗凝药，旨在解决抗凝治疗中未满足的需求 [7] - tecarfarin是一种可逆抗凝剂，旨在为需要长期抗凝的患者预防心脏病发作、中风和由血栓引起的死亡 [10] - tecarfarin已获得孤儿药认定和快速通道资格，用于预防终末期肾病患者的心源性系统性血栓栓塞 [11]